<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To evaluate the clinical relevance of multidrug resistance (<z:chebi fb="14" ids="53218">MDR</z:chebi>) phenotype, the intracellular <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> accumulation (IDA) and P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (P-gp) expression were investigated in 87 adult patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>: 69 patients with de novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 10 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> at relapse, and eight with secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> to <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>IDA and P-gp expression were determined by double-labeling flow cytometry analysis </plain></SENT>
<SENT sid="2" pm="."><plain>Of 87 patients, 36 expressed P-gp (41%) </plain></SENT>
<SENT sid="3" pm="."><plain>P-gp expression was more frequently observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> at relapse and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> as compared with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P = .0001) </plain></SENT>
<SENT sid="4" pm="."><plain>P-gp expression was significantly associated with CD34 expression (P = .0003) and chromosome 7 abnormalities (P = .027) </plain></SENT>
<SENT sid="5" pm="."><plain>A significantly reduced IDA was observed in P-gp+ as compared with P-gp- patients (P = .0007) </plain></SENT>
<SENT sid="6" pm="."><plain>Of the 87 patients, 51 achieved complete remission (CR) </plain></SENT>
<SENT sid="7" pm="."><plain>A reduced IDA was observed in patients in failure as compared with patients in CR (22% +/- 17% v 42% +/- 21%; P = 10(-4) </plain></SENT>
<SENT sid="8" pm="."><plain>Twelve of 36 P-gp+ patients as compared with 40 of 51 P-gp- patients achieved CR (33% v 78%; P = 10(-4) </plain></SENT>
<SENT sid="9" pm="."><plain>The prognostic value of IDA and P-gp expression was confirmed in multivariate analysis </plain></SENT>
<SENT sid="10" pm="."><plain>These data suggest that the determination of IDA and P-gp expression may be useful in designing therapy for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>